Podsumowanie

Dotychczasowe obserwacje wskazują, że problemy towarzyszące konstrukcji TMA są nadal aktualne. Oznacza to dalsze starania, mające na celu poprawę efektywności metody oraz minimalizację uszkodzeń archiwalnego materiału histopatologicznego.[28] Wprowadzenie gotowych parafinowych bloków-biorców TMA z otworami o średnicach 1-5 mm w miejsce trudnych do wykonania i nietrwałych bloków tworzonych przez samych badaczy było znaczące i potwierdziło, że ten kierunek działań jest możliwy i powinien być kontynuowany.

Zdjęcia: autorów – archiwum prywatne, wytwarzania mikromacierzy – Zakład Radioterapii Katedry Onkologii UM w Łodzi (4)

Piśmiennictwo

1. Jongen VH, Briët JM, de Jong RA et al. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer 2009;19:670-6

2. Kim JY, Lim SJ, Park K et al. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005;97:337-41

3. Fowler JM, Ramirez N, Cohn DE et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol 2005;192:1262-71

4. Shergill IS, Shergill NK, Araya M et al. Tissue microarrays: a current medical research tool. Curr Med Res Opin 2004;20:707-12

5. Fons G, Hasibuan SM, van der Velden J et al. Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol 2007;60:500-3

6. Pick E, McCarthy MM, Kluger HM. Assessing expression of apoptotic markers using large cohort tissue microarrays. Methods Mol Biol 2008;414:83-93

7. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7

8. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol 2008;18:89-97

9. Takikita M, Chung JY, Hewitt SM. Tissue microarrays enabling high-throughput molecular pathology. Curr Opin Biotechnol 2007;18:318-25

10. Chen W, Foran DJ. Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta 2006;564:74-81

11. Gulmann C, O`Grady A. Tissue microarrays: an overview. Curr Diagn Pathol 2003;9:149-54

12. Berman JJ, Edgerton ME, Friedman BA. The tissue microarray data exchange specification: a community-based, open source tool for sharing tissue microarray data. BMC Med Inform Decis Mak 2003;3:5

13. Mirlacher M, Simon R. Recipient block in TMA technique. Methods Mol Biol 2010;664:37-44

14. Tzankov A, Went P, Zimpfer A et al. Tissue microarray technology: principles, pitfalls and perspectives - lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-44

15. Tennstedt P, Köster P, Brüchmann A et al. The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol 2012;40:261-8

16. Simon R, Mirlacher M, Sauter G. Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 2010;664:113-26

17. Cimbaluk D, Rotmensch J, Scudiere J et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 2007;105:138-44

18. Kuefer R, Hofer MD, Gschwend JE et al. Tissue microarrays. High-throughput procedures to verify potential biomarkers. Urologe A 2004;43:659-67

19. Lugli A, Tornillo L, Mirlacher M et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004;122:721-7

20. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 2007;203:169-77

21. Gottwald L, Sęk P, Piekarski J et al. Construction of a tissue microarray with 2 mm-size cores in endometrioid endometrial cancer – factors affecting quality of the recipient block. Biotech Histochem 2012;87:512-8

22. Jongen V, Briët J, de Jong R et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009;112:537-42

23. Sauter G. Representativity of TMA studies. Methods Mol Biol 2010;664:27-35. (241)

24. Graham AD, Faratian D, Rae F et al. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008;52:847-55

25. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8

26. Kajdacsy-Balla A, Geynisman JM, Macias V et al. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 2007;38:113-21

27. Pallares J, Santacana M, Puente S et al. A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma. Anal Quant Cytol Histol 2009;31:217-26

28. Deng FM, Zhao Y, Kong X et al. Construction of tissue microarrays using pre-existing slides as source of tissue when paraffin blocks are unavailable. J Clin Pathol 2013:DOI:10.1136/jclinpath-2012-201171

29. Hernandez BY, Frierson HF, Moskaluk CA et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray . Hum Pathol 2005;36:275-81

30. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8

31. Kong X, Zhao Y, Ksionsk M et al. Radiographic determination of tissue thickness in paraffin blocks: application to the construction of tissue microarrays. Appl Immunohistochem Mol Morphol 2007;15:108-12

32. Kajdacsy-Balla A, Geynisman JM, Macias V et al. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 2007;38:113-21

Do góry